Miami, Florida

Miami, Florida 33180

3 studies enrolling now · 15 studies all time

What they study most

Alopecia Areata, Apathy in Dementia, COVID-19, Hepatic Impairment, Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2, Neurotrophic Keratopathy, Panic Disorder, Renal Impairment, Schizophrenia, Seizures

Studies at this site

• A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — Recruiting now
• A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Running, not enrolling
• A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder — Stopped early
• A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy — Stopped early
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia — Completed
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia — Completed
• A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures — Completed
• A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function — Completed
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine — Completed
• Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy — Completed
• To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function — Completed
• To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function — Completed
• Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 — Stopped early